Breaking News Instant updates and real-time market news.

AGEN

Agenus

$2.76

0.25 (9.96%)

, GSK

GlaxoSmithKline

$38.04

0.17 (0.45%)

11:36
01/03/19
01/03
11:36
01/03/19
11:36

Agenus gets $1M from Gates Foundation to enable QS-21 innovations

Agenus (AGEN) announced that the Bill & Melinda Gates Foundation awarded it a grant of ~$1M to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of Agenus' proprietary QS-21 Stimulonadjuvant, a key component of multiple vaccines targeting infectious and endemic diseases. Agenus' QS-21 Stimulon is a proprietary adjuvant, currently incorporated as part of Glaxo Smith Kline's (GSK) highly efficacious Shingrix vaccine. Additionally, Agenus' QS-21 Stimulonis used in GSK's Mosquirix vaccine and numerous other clinical-stage vaccines, including Agenus' own cancer vaccines. Given the criticality of QS-21 in making vaccines efficacious, Agenus plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative future supply. QS-21 is currently extracted from Chilean soap bark trees, exclusively sourced from a localized area in Chile. "We are delighted to be working in partnership with the Bill & Melinda Gates Foundation in our efforts to revolutionize the way we produce QS-21," said Dr. Garo Armen, Chairman and CEO of Agenus. "The Gates Foundation has recognized the value of consistent supply of high-quality QS-21 to power vaccines. We appreciate their commitment to bringing innovation to drive access to important therapies."

AGEN

Agenus

$2.76

0.25 (9.96%)

GSK

GlaxoSmithKline

$38.04

0.17 (0.45%)

  • 18

    May

AGEN Agenus
$2.76

0.25 (9.96%)

10/19/18
HCWC
10/19/18
NO CHANGE
Target $36
HCWC
Buy
Xoma 'undeservedly and overly punished' after CRL, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Xoma (XOMA) to $36 from $49 after the company's partner Novartis (NVS) disclosed the receipt of a Complete Response Letter from the FDA in response to its application for the claim of cardiovascular risk reduction filed for canakinumab. Though canakinumab is one of the lead contributors to Xoma's valuation, the company's shares have been "undeservedly and overly punished," Pantginis tells investors in a research note. He remains focused on Xoma continuing to diversify its risk profile, highlighted by its recent Agenus (AGEN) transaction. He believes the company's numerous "shots on goal" present a "compelling opportunity" at current share levels.
GSK GlaxoSmithKline
$38.04

0.17 (0.45%)

12/14/18
12/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Wedbush and a Hold at Deutsche Bank. 2. New York Times (NYT) initiated with an Outperform at Evercore ISI. 3. Ford (F) and General Motors (GM) were initiated with a Buy at Deutsche Bank, while Autoliv (ALV) was initiated with a Sell. 4. AstraZeneca (AZN) initiated with a Buy at SunTrust while GlaxoSmithKline (GSK) was initiated with a Hold. 5. DaVita (DVA) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/20/18
WELS
12/20/18
NO CHANGE
WELS
Drug industry facing 'brave new world' with drug price scrutiny, says Wells
After Reuters reported that nearly 30 drugmakers are planning to raise the prices of their medicines in the U.S. starting in January, including Novartis (NVS), Bayer (BAYRY), GlaxoSmithKline (GSK), Amgen (AMGN), AstraZeneca (AZN), Biogen (BIIB) and Allergan (AGN), Wells Fargo analyst David Maris told investors in a research note that he has repeatedly highlighted how the practice of drug price increases is a risk for the industry, and believes the latest actions by these manufacturers will be "front and center" for the Trump administration heading towards an election year. He also expects to see increased political and legislative pressure on drug prices as Democrats take over the House in January, and continues to believe that the drug industry is facing a "brave new world" with greater scrutiny of drug prices, lower price increases vs. historical levels, and as a result potentially lower profit margins.
12/27/18
ARGS
12/27/18
NO CHANGE
Target $47
ARGS
Buy
GlaxoSmithKline's high dividend yield 'attractive', says Argus
Argus analyst John Eade kept his Buy rating and $47 price target on GlaxoSmithKline (GSK) with a positive view on its planned joint venture with Pfizer (PFE) combining the companies' consumer businesses. The analyst expects the transaction to boost GlaxoSmithKline shares in the next 2-3 years. Eade also cites the company's 5.2% dividend yield, which he sees as "attractive in a low-interest-rate environment."

TODAY'S FREE FLY STORIES

DDAIF

Daimler AG

$0.00

(0.00%)

09:32
11/14/19
11/14
09:32
11/14/19
09:32
Periodicals
Daimler CEO gets 'reality check' about robotaxis, Reuters reports »

Daimler CEO Ola…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$148.69

10.13 (7.31%)

09:31
11/14/19
11/14
09:31
11/14/19
09:31
Recommendations
Disney analyst commentary  »

Rosenblatt sees potential…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRAH

PRA Health

09:31
11/14/19
11/14
09:31
11/14/19
09:31
Upgrade
PRA Health rating change  »

PRA Health upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

IQV

Iqvia

$143.59

0.5 (0.35%)

09:31
11/14/19
11/14
09:31
11/14/19
09:31
Upgrade
Iqvia rating change  »

Iqvia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PEG

PSEG

$61.06

0.6 (0.99%)

09:30
11/14/19
11/14
09:30
11/14/19
09:30
Downgrade
PSEG rating change  »

PSEG downgraded to Peer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$124.60

-0.25 (-0.20%)

09:30
11/14/19
11/14
09:30
11/14/19
09:30
Downgrade
Splunk rating change  »

Splunk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

09:30
11/14/19
11/14
09:30
11/14/19
09:30
Conference/Events
Federal Reserve Bank of San Francisco to hold a conference »

Asia Economic Policy…

PRPO

Precipio

$2.33

-0.02 (-0.85%)

09:29
11/14/19
11/14
09:29
11/14/19
09:29
Hot Stocks
Precipio announces preliminary results from IV-Cell Media comparative study »

Precipio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGC

Hercules Capital

$14.02

0.03 (0.21%)

, ARCC

Ares Capital

$18.66

0.055 (0.30%)

09:29
11/14/19
11/14
09:29
11/14/19
09:29
Conference/Events
Jefferies to hold a conference »

4th Annual BDC Frankfurt…

HTGC

Hercules Capital

$14.02

0.03 (0.21%)

ARCC

Ares Capital

$18.66

0.055 (0.30%)

AINV

Apollo Investment

$16.34

-0.08 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

09:28
11/14/19
11/14
09:28
11/14/19
09:28
Conference/Events
Needham to hold a conference »

9th Annual Needham SaaS…

PSNL

Personalis

$10.92

0.745 (7.33%)

09:27
11/14/19
11/14
09:27
11/14/19
09:27
Recommendations
Personalis analyst commentary  »

Personalis price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

CAGDF

Centerra Gold

$0.00

(0.00%)

09:27
11/14/19
11/14
09:27
11/14/19
09:27
Hot Stocks
Centerra Gold commences crushing, stacking ore at Oksut Project »

Centerra Gold announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:26
11/14/19
11/14
09:26
11/14/19
09:26
Conference/Events
TD Securities to hold a conference »

2019 Technology…

TPCO

Tribune Publishing

$9.60

-0.2 (-2.04%)

09:26
11/14/19
11/14
09:26
11/14/19
09:26
Hot Stocks
Tribune Publishing declares inital quarterly cash dividend of 25c per share »

Tribune Publishing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/14/19
11/14
09:25
11/14/19
09:25
Conference/Events
Wells Fargo to hold a conference »

2019 Investor IT Boot…

OSW

OneSpaWorld

$15.05

-1.06 (-6.58%)

09:25
11/14/19
11/14
09:25
11/14/19
09:25
Recommendations
OneSpaWorld analyst commentary  »

OneSpaWorld weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSYS

Stratasys

$18.35

-2.39 (-11.52%)

09:25
11/14/19
11/14
09:25
11/14/19
09:25
Recommendations
Stratasys analyst commentary  »

Stratasys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
11/14/19
11/14
09:25
11/14/19
09:25
General news
Fed VC Clarida said the economy is at or close to maximum employment and price stability »

Fed VC Clarida said the…

EPAC

Enerpac Tool

$24.81

-0.935 (-3.63%)

09:25
11/14/19
11/14
09:25
11/14/19
09:25
Conference/Events
Enerpac Tool to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

INSO

Inso Corporation

$0.00

(0.00%)

09:24
11/14/19
11/14
09:24
11/14/19
09:24
Hot Stocks
Inso Corporation enters agreement with Turnagain Herb Company »

INDUSTRY SOURCE…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MITT

AG Mortgage

$15.46

-0.045 (-0.29%)

, AGNC

AGNC Investment

$17.39

0.08 (0.46%)

09:24
11/14/19
11/14
09:24
11/14/19
09:24
Conference/Events
JMP securities to hold a conference »

Financial Services…

MITT

AG Mortgage

$15.46

-0.045 (-0.29%)

AGNC

AGNC Investment

$17.39

0.08 (0.46%)

WMC

Western Asset Mortgage

$10.24

(0.00%)

SYF

Synchrony

$36.57

-0.315 (-0.85%)

PRA

ProAssurance

$38.71

-0.37 (-0.95%)

RC

Ready Capital

$15.84

-0.04 (-0.25%)

MVC

MVC Capital

$9.00

0.005 (0.06%)

MRCC

Monroe Capital

$10.97

(0.00%)

IVR

Invesco Mortgage

$16.11

-0.02 (-0.12%)

AJX

Great Ajax

$15.14

-0.185 (-1.21%)

GHL

Greenhill & Co.

$17.37

-0.76 (-4.19%)

HCI

HCI Group

$44.65

-0.16 (-0.36%)

HTGC

Hercules Capital

$14.02

0.03 (0.21%)

LASR

nLight

$17.14

0.03 (0.18%)

KKR

KKR

$29.38

-0.03 (-0.10%)

CHMI

Cherry Hill Mortgage

$14.55

0.12 (0.83%)

ARI

Apollo Commercial

$17.90

-0.11 (-0.61%)

TCPC

TCP Capital

$14.25

-0.1 (-0.70%)

XAN

Exantas Capital

$11.77

0.02 (0.17%)

FNHC

Federated National

$13.83

-0.18 (-1.28%)

HMN

Horace Mann

$44.16

-0.92 (-2.04%)

MC

Moelis

$33.99

-1.21 (-3.44%)

MRLN

Marlin Business

$20.32

-1 (-4.69%)

ONDK

On Deck Capital

$4.34

-0.1 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 20

    Nov

  • 02

    Dec

  • 09

    Dec

  • 17

    Dec

  • 18

    Dec

GLXZ

Galaxy Gaming

$0.00

(0.00%)

09:23
11/14/19
11/14
09:23
11/14/19
09:23
Earnings
Galaxy Gaming reports Q3 EPS 3c vs. 2c last year »

"We are pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACU

Acme United

$20.37

-0.43 (-2.07%)

09:22
11/14/19
11/14
09:22
11/14/19
09:22
Hot Stocks
Acme United board approves stock repurchase program up to 200,000 shares »

Acme United Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVAV

AeroVironment

$61.51

0.53 (0.87%)

09:22
11/14/19
11/14
09:22
11/14/19
09:22
Hot Stocks
AeroVironment awarded $12M support contract from middle Eastern ally »

AeroVironment announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

09:20
11/14/19
11/14
09:20
11/14/19
09:20
Conference/Events
The Cato Institute to hold a conference »

37th Annual Monetary…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.